SCARLETRED Recognized in the AI Landscape 2024: Highlighted in the Life Science, Health & Med Tech category, SCARLETRED continues to lead AI-driven digital health innovation, contributing to Austria’s thriving AI ecosystem.

SCARLETRED®Vision Now on Android! Our CE-Class I Medical Device Certified app for AI-powered skin imaging and analysis is now available for Android, enabling access for patients, professionals, and new markets worldwide.

Scarletred is honored to represent Austria at EXPO 2025 in Osaka, showcasing innovative Scarletred® AI in the Austrian Pavilion. Join us from April 13 - October 13, 2025, to experience the future of technology and healthcare!

Discover our latest publication showcasing the use of AI-powered Scarletred®Vision for the advanced detection and assessment of onychomycosis, a widespread fungal nail infection affecting millions worldwide.

Scarletred joins WKO India's delegation to connect with India’s tech and healthcare leaders, exploring partnerships to expand dermatology solutions. We are excited for impactful insights in this dynamic innovation hub!

We’re excited to attend AUTOMA+ 2024 in Zurich, focused on automation and digitalization in healthcare and pharma. Join us and industry leaders to explore innovations and engage in the discussion with our CEO!

The 8th Dermatology Drug Development Summit in Boston spotlights innovative skin therapies and novel clinical research. As the lead and hosting partner, SCARLETRED’s CEO Harald Schnidar will present on AI-driven skin research

Atopic Dermatitis affects over 230 million people globally. Scarletred®Vision supports effective treatment research and monitoring by enabling precise tracking of skin changes, advancing research and improving patient care.

Our AI-based skin consultation service with Scarletred®Vision at the Seestadt Apotheke in Vienna, Austria, is continuing. Get your customized skin analysis, SPF and skincare recommendations from an expert on site.

Scarletred cooperates with the Seestadt Apotheke to provide customers AI-based personalized skin care consultations and further education about preventing skin diseases, cancer, and ageing caused by exposure to UV rays.

SCARLETRED will present two studies at the Annual ESDR Meeting, Sept 4-7, 2024, in Lisbon, Portugal. The event features frontier talks, presentations, posters, and workshops, attracting over 1000 dermatology experts globally.

Join our CEO Harald Schnidar's talk "AI powered Digital Dermatology in Skin Drug Research" at the Xista Talk hosted by the Austrian Institute of Science and Technology (ISTA).

SCARLETRED is sponsoring another great event to network with Japanese and Austrian representatives to discuss business and economic-related topics while enjoying Japanese culture. Join the event for free from 9 am.

Scarletred continues its successful partnership with the 5th Dermatology Drug Development Summit 2024 Europe in Berlin, Germany. CEO Harald Schnidar will speak about AI-assisted objective skin imaging in clinical trials.

CEO Harald Schnidar visits once again the Annual Meeting of the American Academy of Dermatology 2024 in San Diego,California,USA. Take advantage of the numerous dermatology experts and the high impact exhibit hall.

Read our groundbreaking publication establishing the first AI benchmark in automated disease classification in Hidradenitis suppurativa (HS) patients by using Scarletred®Vision und calibrated clinical images.

EU Startup News covers innovative startups and emerging trends in the tech industry and talks about SCARLETRED providing standardization and objective skin analysis as a pioneering digital health scaleup.

We are happy to announce our attendance at the 5th Inflammatory Skin Disease Summit: The Translational Revolution to present about smart imaging and deep learning for objective psoriasis lesion scoring.

SCARLETRED is presenting the results of their latest publication at the 32nd EADV Congress in Berlin, Germany. The study examined the use of deep learning algorithms for erythema scoring in radiation-induced dermatitis.

The 7th Dermatology Drug Development Summit in Boston, USA, for inflammatory skin diseases presents novel therapeutics for rare and common skin diseases such as Atopic Dermatitis, Hidradenitis suppurativa, and more.

Striving to develop and expand Scarletred®Vision’s telemedicine applications, we are happy to invite medical doctors to join our Discovery Program to include our software in clinical routine procedures free of cost.

Mariana Karepova shares her insights into the world of innovations and ideas while being president at the Austrian patent office and Scarletred being her favorite one in the last years.

The study uses photobiomodulation at different wavelengths for wound care in diabetic wounds and resulted in signficant positive effects objectively shown by the medical device software Scarletred®Vision.

In the B&C Group's podcast Über:Mut, Scarletred's CEO Harald Schnidar discusses together with Mariana Karepova, President of the Austrian Patent Office, the protection and potential of innovations in Austria.

Scarletred’s CEO Harald Schnidar joins the Dermatology Drug Development Summit 2023 Europe in Berlin, Germany, to speak on the topic of AI-assisted objective skin imaging and analysis.

Topical Bimiralisib, used in patients with the rare cutaneous form of T-cell lymphoma, known as Mycosis fungoides, and healthy patients, showed substantial results regarding cutaneous drug levels.

Our CEO Harald Schnidar is invited to present the results of a cooperation with GALDERMA and the University of Tübingen, wherein Scarletred®Vision confirmed the therapeutic efficacy of Ivermectin in Rosacea patients.

Discover our newest publication about Ivermectin treatment in rosacea patients in cooperation with the university clinic Tübingen, Germany, and how Scarletred®Vision helped monitor signs and symptoms. 

Die Seestadt Apotheke in 1220, Wien, lädt zu ihrem kosmetischen Beratungstag am 29.11.2022 ein. Unterstützt durch Produkte von Eucerin, wird Scarletred exklusiv helfen den Hautzustand zu erfassen und analysieren.

The 6th Dermatology Drug Development Summit for inflammatory skin diseases gives insight into novel therapeutics and patient-specific and alternative treatment options currently in clinical trials for various skin diseases.

The life science and pharmaceutical fair takes place October 11-14th to bring together innovative companies, customers, and investors. SCARLETRED is one of nine companies representing the Austrian Economic Chambers in Tokyo.

Our published paper about machine learning and developing the SEV value will be presented at the ÖGRO annual congress in Villach, Austria, with our collaborator at the Landeskrankenhaus Graz, Dr. Richard Partl.

​​SCARLETRED is visiting and presenting at this year´s 51st Annual ESDR Summit taking place in Amsterdam, Netherlands between 28th September - 1st October 2022.

SCARLETRED visits the hybrid EADV congress in Milan from September 7-9, 2022, to present the results of a new rosacea study that used Scarletred®Vision to measure the effectiveness of a new treatment.

We are excited to announce that SCARLETRED has received a new EC declaration of conformity approving Scarletred®Vision as a physiological measuring system and a CE Class 1m medical device.

After 3 years, the well-renowned women's conference, Global Female Leaders Summit, will take place from the 8th-10th of May 2022 at the Adlon Hotel Kempinski in Berlin, Germany.

Post-Marketing Studies play an integral role in gathering information about safety and efficacy on a large scale. However, monitoring adverse events and patient-reported outcomes in a real-world setting can be challenging.

A study, performed by the Medical University of Vienna, examined diagnostic accuracy of SARS-CoV-2 rapid antigen tests compared to RT-PCR as the gold standard based on different swab sites by using Scarletred®Vision.

Following a successful launch in Europe in 2019, and a tremendous online experience in 2021, the 3rd Dermatology Drug Development Europe Summit, returns in April 2022 in Frankfurt, Germany.

The DP aims to collaborate with pharmaceutical and biotechnology companies by providing access to our customizable software Scarletred®Vision for exploratory or early-stage clinical studies at a more attractive price point.

SCARLETRED is currently featured at the Arab Health 2022 exhibition in Dubai, among other companies in medical and healthcare-related categories. The networking event helps to connect and support innovations in healthcare.

The EXPO 2020 “Connecting Minds, Creating the Future” theme addresses visions of a networked and technology-based future. SCARLETRED is currently exhibited in the iLab section representing the future of digital healthcare.

The business magazine Gewinn discusses how Scarletred®Vision is an excellent addition to the safety and monitoring of injection site reactions (ISRs) in vaccine development.

The national platform IÖB (public procurement promoting innovation) announced Austria’s top innovations. This year, the IÖB awarded SCARLETRED with Scarletred®Vision as a digital healthcare management solution.

The popular newspaper Der Standard features the recent milestones of SCARLETRED in the field of teledermatology. With these, SCARLETRED sets the benchmark for AI-Assisted Screening in telemedicine and radiation oncology.

In an interview, specialist Dr. Zikeli discusses the clinical characteristics of atopic dermatitis and why documentation using Scarletred®Vision is an optimal support for diagnosis and progress monitoring.

The 5th Annual Dermatology Drug Development Summit focusing on development and innovation of therapies and research targeting inflammatory skin diseases, returns to Boston for 2021.

The Inflammatory Skin Disease Summit is a jointly organized event by the Icahn School of Medicine at Mount Sinai and the Austrian Academy of Sciences.

The clinically validated and award-winning technology, Scarletred®Vision, is on market since 2015, enabling high quality remote skin imaging and objective analysis in over 3000 cutaneous disorders.

​​In the round table discussion of the leading financial domain Börse Express, Marinomed, Scarletred, PHH Rechtsanwälte, and EOSS Industries discussed the development and hurdles of Austrian life science start-ups.

The EXPO 2020 “Connecting Minds, Creating the Future” theme addresses visions of a more networked and technology-based future, covering topics from smart city over sustainability to digital healthcare.

International team of four talented students has won a 3rd place on WSA Youth for Innovation case study competition by solving Scarletred´s challenge on injection site reactions.

The research award has been awarded annually by the B&C Private Foundation. With the Houska Prize, the B&C private foundation is committed to improving research conditions and cutting-edge research in Austria.

Wien (OTS) - Videokonferenzen, Home Schooling, Online-Yogastunden – die aktuelle Corona-Situation hat eindrücklich bewiesen, wie wichtig digitale Kommunikation für alle Lebensbereiche geworden ist.

SeneCura is currently using the CE-certified medical device of Scarletred in eleven care facilities, after which a roll-out to every SeneCura facilities in Austria is planned.

Der Houskapreis ist Österreichs größter privater Forschungspreis. Insgesamt 500.000 Euro vergibt die B&C Privatstiftung für Spitzenforschung aus Österreich.

Following a call from the City of Vienna for 5G use case entries in autumn 2019, Azoome and Scarletred, with A1 as their technology partner, have won awards for education and healthcare. Funded pilots will begin this year.

Last week SCARLETRED won the Japanese TechBIZKON – Digital Health beyond 2020 Award! We want to say thanks to the audience for their strong vote and to EDGEof for making this great digital health event possible.

In 2014, while conducting a clinical trial, Dr. Harald Schnidar percieved the need of a technology that allows to objectify dermatological assessments. Reacting to the lack of a suitable solution, he founded SCARLETRED.

The GEWINN YOUNG ENTREPRENEUR competition took place for the 30th time, there were about 1,000 first registrations, of which 300 were judged and we are happy to say that SCARLETRED was positioned 7th in the final 100!